TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 1, 2009, Pages 72-81

  Joshi, Deepa ^a   Gupta, Ram ^a   Dubey, Amita ^a   Shiwalkar, Ajay ^a   Pathak, Padmaja ^a   Gupta, Ramesh C ^a   Chauthaiwale, Vijay ^a   Dutt, Chaitanya ^a  

^a Torrent Pharmaceuticals Ltd   (India)

Author keywords

AGE breaker; Cardiomyopathy; Diabetes; Nephropathy; TRC4186

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION ENDPRODUCT RECEPTOR BLOCKING AGENT; ALBUMIN; BRAIN NATRIURETIC PEPTIDE; CREATININE; DRUG VEHICLE; INTERLEUKIN 6; TRC 4149; TRC 4186; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; HEART OUTPUT; HISTOPATHOLOGY; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; ZUCKER DIABETIC FATTY RAT;

ANIMALS; CARDIOMYOPATHIES; CROSSES, GENETIC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOSYLATION END PRODUCTS, ADVANCED; MALE; PYRIDINIUM COMPOUNDS; RATS; RATS, INBRED SHR; RATS, ZUCKER; SULFONAMIDES;

EID: 68249149199     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181ac3a34     Document Type: Article

References (39)

1. Vlassara H, Striker LJ, Teichberg S, et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA. 1994;91:11704-11708. (Pubitemid 24356413)
2. Tsuchida K, Makita Z, Yamagishi S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia. 1999;42:579-588.
3. Cerami A, Vlassara H, Brownlee M. Protein glycosylation and the pathogenesis of atherosclerosis. Metabolism. 1985;34:37-42.
4. Bucala R, Makita Z, Koschinsky T, et al. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA. 1993;90: 6434-6438. (Pubitemid 23207227)
5. Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003;92:785-792. (Pubitemid 36457644)
6. Daoud S, Schinzel R, Neumann A, et al. Advanced glycation endproducts: activators of cardiac remodeling in primary fibroblasts from adult rat hearts. Mol Med. 2001;7:543-551. (Pubitemid 33701960)
7. Bidasee KR, Zhang Y, Shao CH, et al. Diabetes increases formation of advanced glycation end products on sarco(endo)plasmic reticulum Ca2-ATPase. Diabetes. 2004;53:463-473. (Pubitemid 38174564)
8. Quehenberger P, Bierhaus A, Fasching P, et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes. 2000;49:1561-1570. (Pubitemid 30677250)
9. Sanders DB, Kelley T, Larson D. The role of nitric oxide synthase/nitric oxide in vascular smooth muscle control. Perfusion. 2000;15:97-104. (Pubitemid 30182409)
10. Pathak P, Gupta R, Chaudhari A, et al. TRC4149 a novel advanced glycation end product breaker improves hemodynamics status in diabetic spontaneously hypertensive rats. Eur J Med Res. 2008;13:388-398.
11. National Institutes of Health. Principles of Laboratory Animal Care. NIH publication No. 85-123, revised 1985.
12. CPCSEA Guidelines for Laboratory Animal Facility. Committee for the Purpose of Control and Supervision on Experiments on Animals. Ind J Pharmacol. 2003;35:257-274.
13. Luna LG. Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology, Third Edition. New York: McGraw-Hill; 1968.
14. Tofovic SP, Kusaka H, Kost CK Jr, et al. Renal function and structure in diabetic, hypertensive, obese ZDFxSHHF-hybrid rats. Ren Fail. 2000;22: 387-406. (Pubitemid 30441636)
15. Tofovic SP, Jackson EK. Rat model of metabolic syndrome. Methods Mol Med. 2003;86:29-46.
16. Hartog JW, Voors AA, Schalkwijk CG, et al. Clinical and prognostic value of advanced glycation end-products in chronic heart failure. Eur Heart J. 2007;28:2879-2885. (Pubitemid 350233041)
17. Connelly KA, Kelly DJ, Zhang Y, et al. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res. 2007;76:280-291. (Pubitemid 350214455)
18. De Keulenaer GW, Brutsaert DL. Systolic and diastolic heart failure: different phenotypes of the same disease? Eur J Heart Fail. 2007;9: 136-143.
19. Riva E, Andreoni G, Bianchi R, et al. Changes in diastolic function and hypertensive rats with long-term streptozotocin-induced diabetes. Pharmacol Res. 1998;37:233-240.
20. Loganathan R, Bilgen M, Al-Hafez B, et al. Cardiac dysfunction in the diabetic rat: quantitative evaluation using high resolution magnetic resonance imaging. Cardiovasc Diabetol. 2006;5:7-14.
21. Nemoto O, Kawaguchi M, Yaoita H, et al. Left ventricular dysfunction and remodeling in streptozotocin-induced diabetic rats. Circ J. 2006;70: 327-334. (Pubitemid 43312257)
22. Cosyns B, Droogmans S, Weytjens C, et al. Effect of streptozotocin- induced diabetes on left ventricular function in adult rats: an in vivo Pinhole Gated SPECT study. Cardiovasc Diabetol. 2007;6:30. (Pubitemid 350226872)
23. Fredersdorf S, Thumann C, Ulucan C, et al. Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc Pathol. 2004;13:11-19. (Pubitemid 38169461)
24. Westermann D, Van LS, Dhayat S, et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol. 2007;102: 500-507. (Pubitemid 47578394)
25. Chowdhry MF, Vohra HA, Galiñanes M. Diabetes increases apoptosis and necrosis in both ischemic and non-ischemic human myocardium: Role of caspases and poly-adenosine diphosphate-ribose polymerase. J Thorac Cardiovasc Surg. 2007;134:124-131. (Pubitemid 46962014)
26. Gabriely I, Yang XM, Cases JA, et al. Hyperglycemia modulates angiotensinogen gene expression. Am J Physiol Regul Integr Comp Physiol. 2001;281:R795-R802. (Pubitemid 32885093)
27. Hsieh TJ, Zhang SL, Filep JG, et al. High glucose stimulates angio-tensinogen gene expression via reactive oxygen species generation in rat kidney proximal tubular cells. Endocrinology. 2002;143:2975-2985. (Pubitemid 34809870)
28. Miller JA. Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol. 1999;10: 1778-1785.
29. Farhangkhoee H, Khan ZA, Kaur H, et al. Vascular endothelial dysfunction in diabetic cardiomyopathy: Pathogenesis and potential treatment targets. Pharmacol Ther. 2006;111:384-399. (Pubitemid 43832002)
30. Sys SU, Brutsaert DL. Diagnostic significance of impaired lv systolic relaxation in heart failure. Circulation. 1995;92:3377-3380.
31. Soulis-Liparota T, Cooper M, Papazoglou D, et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes. 1991;40:1328-1334.
32. Damman K, Navis G, Smilde TD, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail. 2007;9:872-878. (Pubitemid 47332311)
33. Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation. 1996;93:1905-1912. (Pubitemid 26154042)
34. Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis. 1995;26:875-888.
35. Wolffenbuttel BH, Boulanger CM, Crijns F, et al. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA. 1998;95:4630-4634. (Pubitemid 128620785)
36. Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003;92:785-792. (Pubitemid 36457644)
37. Peppa M, Brem H, Cai W, et al. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711). Am J Nephrol. 2006;26:430-436. (Pubitemid 44971733)
38. Zieman SJ, Melenovsky V, Clattenburg L, et al. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens. 2007;25: 577-583. (Pubitemid 46213796)
39. Little WC, Zile MR, Kitzman DW, et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005;11:191-195.